Hepatic Encephalopathy - Pipeline Review, H2 2016

Date: July 13, 2016
Pages: 64
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: H9F312D2C87EN
Leaflet:

Download PDF Leaflet

Hepatic Encephalopathy - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘Hepatic Encephalopathy - Pipeline Review, H2 2016’, provides an overview of the Hepatic Encephalopathy pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Hepatic Encephalopathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hepatic Encephalopathy and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope
  • The report provides a snapshot of the global therapeutic landscape of Hepatic Encephalopathy
  • The report reviews pipeline therapeutics for Hepatic Encephalopathy by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Hepatic Encephalopathy therapeutics and enlists all their major and minor projects
  • The report assesses Hepatic Encephalopathy therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Hepatic Encephalopathy
Reasons to buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Hepatic Encephalopathy
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Hepatic Encephalopathy pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Global Markets Direct Report Coverage
Hepatic Encephalopathy Overview
Therapeutics Development
Pipeline Products for Hepatic Encephalopathy - Overview
Hepatic Encephalopathy - Therapeutics under Development by Companies
Hepatic Encephalopathy - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Unknown Stage Products
Hepatic Encephalopathy - Products under Development by Companies
Hepatic Encephalopathy - Companies Involved in Therapeutics Development
Alfa Wassermann S.p.A
Cosmo Pharmaceuticals S.p.A
Horizon Pharma Plc
KannaLife Sciences, Inc.
Ocera Therapeutics, Inc.
Rebiotix Inc.
Spherium Biomed S.L.
Umecrine Cognition AB
Hepatic Encephalopathy - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
glycerol phenylbutyrate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GR-3027 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KLS-13019 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ornithine phenylacetate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RBX-2477 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rifamycin CR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rifaximin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
THDP-17 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Hepatic Encephalopathy - Dormant Projects
Hepatic Encephalopathy - Product Development Milestones
Featured News & Press Releases
Apr 15, 2016: Ocera Therapeutics Announces Presentation of Two Preclinical Studies Further Supporting Its Ammonia Scavenger OCR-002 at The International Liver Congress 2016 of the European Association for the Study of the Liver (EASL)
Apr 11, 2016: Ocera Therapeutics Announces Publication of Promising Preclinical Data in Support of Its Ammonia Scavenger OCR-002 in the Journal of Hepatology
Jan 08, 2016: Ocera Announces Complete Plasma Data From Pilot Phase 1 Study for Orally-Available OCR-002 in Development for the Prevention of Chronic Hepatic Encephalopathy
Dec 09, 2015: Umecrine Cognition Announces Grant Of a US Patent Protecting Its Lead Candidate Drug GR3027
Nov 16, 2015: Ocera Announces Positive Phase 1 Results for Oral OCR-002 in Development for the Prevention of Chronic Hepatic Encephalopathy
Sep 16, 2015: Ocera Initiates Phase 1 Clinical Trial of Oral Drug Candidate OCR-002 for Prevention of Hepatic Encephalopathy
Aug 19, 2015: Umecrine Cognition announces the publication of preclinical results of the candidate drug GR3027 aimed for the treatment of hepatic encephalopathy
Aug 11, 2015: Kannalife Sciences Discusses Orphan Drug Opportunity for KLS-13019
Apr 20, 2015: Lupin Launches Zaxine in Canada
Apr 01, 2015: Ocera Completes Interim Analysis of OCR-002 in Phase 2b STOP-HE Study for the Treatment of Acute Hepatic Encephalopathy
Sep 18, 2014: Salix Secures Additional Intellectual Property Relating to Rifaximin
Sep 12, 2014: Lupin and Salix Announce Exclusive Distribution Agreement for Zaxine in Canada
Feb 25, 2014: Hyperion Therapeutics Announces the Publication of Phase 2 Results of Glycerol Phenylbutyrate for the Treatment of Hepatic Encephalopathy in Hepatology
Feb 14, 2014: Luxembourg National Health Fund Approves Reimbursement Of Xifaxan 550
Feb 04, 2014: Salix Pharmaceuticals Announces Issuance Of U. S. Patent For Rifaximin
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Hepatic Encephalopathy, H2 2016
Number of Products under Development by Companies, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Comparative Analysis by Unknown Stage Development, H2 2016
Products under Development by Companies, H2 2016
Hepatic Encephalopathy - Pipeline by Alfa Wassermann S.p.A, H2 2016
Hepatic Encephalopathy - Pipeline by Cosmo Pharmaceuticals S.p.A, H2 2016
Hepatic Encephalopathy - Pipeline by Horizon Pharma Plc, H2 2016
Hepatic Encephalopathy - Pipeline by KannaLife Sciences, Inc., H2 2016
Hepatic Encephalopathy - Pipeline by Ocera Therapeutics, Inc., H2 2016
Hepatic Encephalopathy - Pipeline by Rebiotix Inc., H2 2016
Hepatic Encephalopathy - Pipeline by Spherium Biomed S.L., H2 2016
Hepatic Encephalopathy - Pipeline by Umecrine Cognition AB, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Hepatic Encephalopathy - Dormant Projects, H2 2016

LIST OF FIGURES

Number of Products under Development for Hepatic Encephalopathy, H2 2016
Number of Products under Development by Companies, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Targets, H2 2016
Number of Products by Stage and Targets, H2 2016
Number of Products by Mechanism of Actions, H2 2016
Number of Products by Stage and Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Types, H2 2016
Skip to top


Hepatitis C - Pipeline Review, H2 2016 US$ 2,000.00 Sep, 2016 · 523 pages
Hepatitis B - Pipeline Review, H2 2015 US$ 1,700.00 Nov, 2015 · 385 pages

Ask Your Question

Hepatic Encephalopathy - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: